The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genomic Health; Lilly; MSD Oncology; Nektar; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Tesaro; Teva
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Hexal; Lilly; Nektar; Roche
Research Funding - Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer; Roche
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Merck; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
 
Rashmi Krishna Murthy
Honoraria - Daiichi Sankyo; Genentech; Puma Biotechnology; Puma Biotechnology; Seagen
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Puma Biotechnology; Puma Biotechnology; Seagen
Research Funding - Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Genentech; Puma Biotechnology; Puma Biotechnology; Seagen
 
Carey K. Anders
Honoraria - Eisai; Genentech/Roche; IPSEN; Puma Biotechnology; Seagen
Consulting or Advisory Role - Eisai; Genentech/Roche; Ipsen; Puma Biotechnology; Seagen
Research Funding - G1 Therapeutics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Puma Biotechnology (Inst); Seagen (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlett; Up to Date.com
Travel, Accommodations, Expenses - Eisai
 
Virginia F. Borges
Consulting or Advisory Role - Seagen
Research Funding - Abbott/AbbVie (Inst); Millennium (Inst); Seagen (Inst)
 
Sara A. Hurvitz
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst)
Other Relationship - Pfizer; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Vandana G Abramson
Employment - HCA Healthcare (I)
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Eisai
Research Funding - Astellas Pharma; Genentech/Roche; Lilly
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst); SignalChem (Inst)
 
Mafalda Oliveira
Honoraria - Novartis; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Puma Biotechnology; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Celldex (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Philips Healthcare (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; GP Pharm; Grunenthal; Novartis; Pierre Fabre; Roche
 
Amelia Bruce Zelnak
Consulting or Advisory Role - Novartis; Pfizer
Travel, Accommodations, Expenses - Immunomedics
 
Michael DiGiovanna
Research Funding - Cascadian Therapeutics (Inst); Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - DAKO - Royalties; NeoMarkers - Royalties
 
Thomas Bachelot
Consulting or Advisory Role - AstraZeneca; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; pfizer; Roche
 
Amy Jo Chien
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst)
 
Ruth O'Regan
Honoraria - bioTheranostics; Genentech; Genomic Health; Immunomedics; Lilly; Macrogenics; Novartis; Pfizer; Puma Biotechnology
Consulting or Advisory Role - bioTheranostics; Genentech; Genomic Health; ImmunogenX; Lilly; Macrogenics; Novartis; Puma Biotechnology
Research Funding - Cascadian Therapeutics (Inst); Eisai (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Genomic Health; Immunomedics; Lilly; Macrogenics; Puma Biotechnology
 
Andrew M. Wardley
Stock and Other Ownership Interests - Andrew Wardley Limited; Manchester Cancer Academy
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Accord Research; AstraZeneca; AstraZeneca; Athenex; Athenex; Coleman Research; Daiichi Sankyo; Gerson Lehrman Group; Guidepoint Global; Lilly; MSD Oncology; NAPP Pharmaceuticals; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche
Research Funding - Most Cancer Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
Other Relationship - MSD Oncology
 
Volkmar Müller
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - Immunomedics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Syndax (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)
 
Suzanne M. McGoldrick
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie (I)
Research Funding - Abbvie (I); Janssen (I); Takeda (I)
Travel, Accommodations, Expenses - Seagen
 
Grace An
Employment - Novartis; Seagen
Stock and Other Ownership Interests - Seagen
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Carrick Therapeutics; G1 Therapeutics; Genomic Health; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen
Research Funding - Genentech (Inst); Novartis (Inst)